Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Intel Unveils Panther Lake AI Laptop Chips at CES 2025, Marking Major 18A Manufacturing Milestone 
SMIC Shares Climb as China Boosts Chipmaking Support Amid AI Optimism 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Tokyo Electric Power Shares Surge as Kashiwazaki-Kariwa Nuclear Reactor Restart Nears 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
